相关实验视频

Updated: Jun 18, 2025

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Published on: December 1, 2023

绝经后妇女接受胰岛素耐药性乳腺癌治疗:临床,分析,横截面

Claudio Lera Orsatti^1,2,3, Fabio Lera Orsatti², João Pedro Esteves Alves De Souza¹

¹Department of Health Sciences, Universidade do Oeste Paulista - UNOESTE, Jaú, Brazil.

|August 1, 2024

概括

在绝经后的女性中,血清热冲击蛋白70 (HSP70) 与胰岛素抵抗 (IR) 有关,特别是在乳腺癌患者中. 对于热冲击蛋白60 (HSP60) 或细胞因子,没有发现这种关联.

科学领域:

内分泌学在内分泌学.
在瘤学瘤学.
免疫学免疫学免疫学

背景情况:

胰岛素抵抗 (IR) 和炎症与绝经后健康和乳腺癌有关.
热冲击蛋白 (HSP) 参与细胞应激反应,可能在代谢和瘤疾病中发挥作用.

研究的目的:

在绝经后的妇女中,研究细胞因子,热冲击蛋白 (HSP60,HSP70) 和胰岛素耐药性 (常态模型评估IR - HOMA-IR) 的血清水平之间的关联.
为了比较这些标志物在有和没有乳腺癌的绝经后妇女之间.

主要方法:

一项对381名绝经后妇女进行的横截面研究 (94名患有乳腺癌,278名没有).
使用ELISA测量血清细胞因子 (TNF-α,IL-10,IL-6) 和热冲击蛋白 (HSP60,HSP70) 的水平.
分析了人类测量和实验室数据,包括HOMA-IR.

主要成果:

与没有癌症的女性相比,患有乳腺癌的女性表现出更高的HOMA-IR,IL-6,TNF-α和HSP60水平,以及较低的IL-10和HSP70水平.
仅在患有乳腺癌的女性中 (β=0.22,p=0.030) 观察到HSP70和HOMA-IR之间的显著正相关性.
在两组中都没有发现细胞因子,HSP60和HOMA-IR之间的显著关联.

结论:

血清HSP70与被诊断患有乳腺癌的绝经后妇女的胰岛素抵抗有关.
这些发现表明HSP70在这种人群中胰岛素抵抗和乳腺癌之间的相互作用中可能发挥作用.

关键词:

乳腺癌是什么? 乳腺癌是什么在HOMA-IR中,我们可以看到HOMA-IR.心血管疾病的风险.胰岛素耐药性是一种胰岛素耐药性.在更年期后的绝经后.

更多相关视频

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

Assessing Insulin Clearance in Mice via In Situ Liver Perfusion

Assessing Insulin Clearance in Mice via In Situ Liver Perfusion

Published on: December 13, 2024

相关概念视频

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...